Forecast

There is no analyst data available for this company.

News Go to news feed

Cogent Communications bets on wavelength growth and Sprint integration by mid-2028

At the Oppenheimer conference, Cogent Communications outlined targets of $1.5 billion in revenue and $500 million in EBITDA by mid-2028, driven by the Sprint acquisition and expansion of its wavelength business. The company plans a market entry in India, is reviewing the sale of non-core assets, and expects sequential revenue growth from Q1 2025 despite short-term declines from Sprint and reduced T‑Mobile subsidies. » More on de.investing.com
Crown Castle starts strategic realignment after $8.5 billion sale

Crown Castle will sell its fiber and small-cell business for $8.5 billion and reposition itself as a pure US tower operator, with $6 billion earmarked to pay down debt and the remainder for share buybacks. The company raised its outlook for tower leasing, is targeting an investment-grade rating, and named Christian Hildenbrand as its new CEO starting in September. Regulatory approvals, including a second request from the US-Justizministerium, are progressing as planned; Sprint churn and minimal effects from the T-Mobile/U.S. Cellular transactions were also noted. » More on de.investing.com

Financials

In the last quarter, SPRINT BIOSCIENCE AB had revenue of €0 and net profit of -€1.46m

(EUR)	June 2026	YoY
Revenue	0	100.00%
Gross profit	-25.27k	103.21%
Net profit	-1.46m	121.02%
EBITDA	-1.47m	155.18%

Fundamentals

Metric	Value
Market capitalization	€27.59m
Number of shares	105.52m
52-week high/low	€0.41 - €0.047
Dividends	No
Beta	-0.52
P/E ratio	4.10
PEG ratio	0.01
P/B ratio	3.46
P/S ratio	2.24

Company profile

Sprint Bioscience AB (publ) entwickelt pharmazeutische Produkte in den Bereichen Krebs und Stoffwechsel in Schweden, Europa, den Vereinigten Staaten und Asien. Das Unternehmen entwickelt VPS34, einen Arzneimittelkandidaten für die Behandlung verschiedener Krebsarten, und PETRA01, einen Arzneimittelkandidaten für die Behandlung von Krebs. Das Unternehmen konzentriert sich auch auf die Erforschung von Produkten für die Behandlung des Tumorstoffwechsels und von Typ-2-Diabetes. Sprint Bioscience AB (publ) wurde 2009 gegründet und hat seinen Sitz in Huddinge, Schweden.